Clinical Trials
9 trialsNCT02689427 2026-05-12
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02007512 2025-09-02
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Phase 2 Completed
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02091960 2025-04-04
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT01889238 2024-12-13
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Pfizer
Phase 2 Completed
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT02457910 2022-08-22
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated
NCT02953860 2021-05-14
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed